NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis $11.69 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$11.68 -0.01 (-0.13%) As of 06/18/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Delcath Systems Stock (NASDAQ:DCTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Delcath Systems alerts:Sign Up Key Stats Today's Range$11.64▼$12.1850-Day Range$9.88▼$11.9352-Week Range$8.12▼$14.48Volume582,701 shsAverage Volume550,134 shsMarket Capitalization$403.54 millionP/E Ratio1,169.00Dividend YieldN/APrice Target$22.50Consensus RatingHold Company Overview Delcath Systems, Inc. is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma. Delcath’s approach aims to improve tumor response rates and extend progression-free survival for patients with limited treatment options. The Hepatic CHEMOSAT® Delivery System comprises specialized catheters, an extracorporeal filtration system and an isolation balloon that together isolate the liver’s vasculature, deliver high-dose chemotherapy and filter the returned blood before it reenters the patient’s systemic circulation. Delcath has achieved CE Mark approval in Europe for the treatment of unresectable liver tumors and is advancing its clinical development program in the United States, where it has completed pivotal trials assessing safety and efficacy in patients with ocular melanoma metastases in the liver. The company also continues to explore expanded indications and next-generation applications of its chemosaturation platform. Headquartered in New York, Delcath Systems operates in key oncology markets across North America and Europe, collaborating with leading cancer centers and interventional radiology departments. The organization is guided by a management team and board of directors with experience in medical device commercialization, oncology drug development and regulatory affairs. Delcath remains committed to advancing targeted regional therapies that address unmet needs in the treatment of liver tumors and improving patient outcomes through innovation and rigorous clinical investigation.AI Generated. May Contain Errors. Read More Delcath Systems Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreDCTH MarketRank™: Delcath Systems scored higher than 45% of companies evaluated by MarketBeat, and ranked 527th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingDelcath Systems has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialDelcath Systems has a consensus price target of $22.50, representing about 92.5% upside from its current price of $11.69.Amount of Analyst CoverageDelcath Systems has only been the subject of 2 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Delcath Systems are expected to decrease in the coming year, from ($0.88) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is 1,169.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 43.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is 1,169.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.94.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.17% of the float of Delcath Systems has been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 7.38.Change versus previous monthShort interest in Delcath Systems has recently decreased by 9.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest5 people have searched for DCTH on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders19.36% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCTH Stock News HeadlinesDelcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Consensus PT from AnalystsJune 13, 2026 | americanbankingnews.comDelcath Shareholders Approve Expanded Equity Plan and GovernanceMay 25, 2026 | theglobeandmail.comHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.June 20 at 1:00 AM | InvestPub (Ad)Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says UndervaluedMay 23, 2026 | gurufocus.comDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 15, 2026 | businesswire.comDelcath Systems Balances Growth with Rising CostsMay 8, 2026 | tipranks.comDelcath (DCTH) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comDelcath outlines at least $100M 2026 revenue as it targets 37 active centers by year-endMay 8, 2026 | msn.comSee More Headlines DCTH Stock Analysis - Frequently Asked Questions How have DCTH shares performed this year? Delcath Systems' stock was trading at $10.10 on January 1st, 2026. Since then, DCTH shares have increased by 15.7% and is now trading at $11.69. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.07. The business had revenue of $24.99 million for the quarter, compared to analysts' expectations of $23.51 million. Delcath Systems had a trailing twelve-month return on equity of 0.51% and a net margin of 0.62%. Read the conference call transcript. When did Delcath Systems' stock split? Delcath Systems shares reverse split on the morning of Tuesday, October 22nd 2019.The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How will Delcath Systems' stock buyback program work? Delcath Systems' board initiated a stock repurchase program on Thursday, November 20th 2025, which allows the company to repurchase $25,000,000 in shares, according to EventVestor. This means that the company could buy up to 8.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company's leadership believes its stock is undervalued. Who are Delcath Systems' major shareholders? Delcath Systems' top institutional investors include Renaissance Technologies LLC (0.45%), Bank of New York Mellon Corp (0.29%), Bank of America Corp DE (0.17%) and Sei Investments Co. (0.13%). Insiders that own company stock include Gil Aharon, Rosalind Advisors, Inc, Gerard J Michel, Vojo Vukovic, John Purpura, Sandra Pennell and John Richard Sylvester. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Delcath Systems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Delcath Systems investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Zomedica (ZOM), Wells Fargo & Company (WFC), Wayfair (W) and Bank of America (BAC). Company Calendar Last Earnings5/07/2026Today6/20/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 DCTH's financial health is in the Red zone, according to TradeSmith. DCTH has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:DCTH CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees60Year Founded1988Price Target and Rating Average Price Target for Delcath Systems$22.50 High Price Target$30.00 Low Price Target$18.00 Potential Upside/Downside+92.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.01 Trailing P/E Ratio1,169.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.70 million Net Margins0.62% Pretax Margin1.48% Return on Equity0.51% Return on Assets0.46% Debt Debt-to-Equity RatioN/A Current Ratio11.24 Quick Ratio10.33 Sales & Book Value Annual Sales$85.23 million Price / Sales4.73 Cash Flow$0.05 per share Price / Cash Flow223.63 Book Value$3.15 per share Price / Book3.71Miscellaneous Outstanding Shares34,520,000Free Float27,839,000Market Cap$403.54 million OptionableOptionable Beta0.54 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:DCTH) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
